The AMP-activated protein kinase (AMPK) regulates metabolic homeostasis and plays a protective role in the ischemic and diabetic hearts. The A-769662 compound, which directly binds and activates AMPK, has recently been characterized. Here, we studied the impact of A-769662 on cardiac AMPK signaling and glucose uptake which is known to participate in the protective action of AMPK.
Methods:
Insulin and/or A-769662 were used to stimulate adult cardiomyocytes. The effect of A-769662 on the action of other AMPK activators has been also tested. Glucose uptake was measured by the detritriation rate of [2- 3 H] glucose. The phosphorylation state of signaling elements was measured by immunoblot. AMPK activity was assessed by the incorporation of radioactive phosphates on a specific synthetic peptide. Cell death and ROS production were evaluated using propidium iodide or by monitoring oxidation of a fluorescent probe, respectively.
Results: Glucose uptake was increased by both insulin and oligomycin. In the presence of insulin, oligomycin leads to an overstimulation of glucose uptake that correlated with an Akt overphopsphorylation. In contrast, A-769662 had no insulin sensitizing effects. Indeed, A-769662 promoted AMPK phosphorylation but did not stimulate glucose uptake and did not induce an overphosphorylation of Akt or an overstimulation of glucose uptake in the presence of insulin. Otherwise, A-769662 potentiates the effects of other AMPK activators. We showed an overphosphorylation of AMPK and of its substrate ACC, when A-769662 was added to oligomycin or hypoxia. This potentiation effect was accompanied by an overstimulation of glucose uptake and by a decrease in cell mortality and ROS production.
Conclusions:
A-769662, by itself, is unable to stimulate glucose uptake or to increase insulin sensitivity. However, its ability of potentiating the action on other AMPK activators makes it a potentially useful participant in the protective role of AMPK in the heart. Background: AMPK activators, like resveratrol or metformin, inhibit pathological cardiac hypertrophy. However, despite evidence for their antihypertrophic effect, it seems that this phenomenon is mainly circumstantial. Indeed, those agents induce a rather non-specific AMPK activation by increasing the AMP/ATP ratio or by mimicking AMP. Hence, the aim of this study was to test the ability of a more specific AMPK activator, called A-769662, to prevent phenylephrine (PE)-induced hypertrophy in cultured neonatal rat ventricular myocytes (NRVM) and in adult rat ventricular myocytes (ARVM).
Method: Alpha-actinin immunostaining, radio labelled amino acid incorporation, nuclear factor of activated T-cells (NFAT) activity, hypertrophylinked gene expression and protein phosphorylation were analysed to determine NRVM hypertrophy. Cell surface area and protein phosphorylation were analysed to define ARVM hypertrophy.
Results: Using dose-response experiments and genetic AMPK silencing, we show here that A-769662 is able to prevent the development of PE-induced NRVM hypertrophy by an AMPK-dependant mechanism. This hypertrophy prevention correlates with the modification of AMPK-related key regulators of cardiac hypertrophy including ~50% lower protein synthesis (p<0.05) and a 3-fold decreased phosphorylation of p70S6K (p<0.05) but also a significant decrease in ERK1/2 (~50%, p<0.05) and NFAT signalling (~90%, p<0.05) when high concentrations of A-769662 were used in combination with PE vs PE alone. However, while low dose of A-769662 (12.5 μM) still efficiently M) still efficiently prevents PE-induced NRVM hypertrophy (p<0.05) none of the known AMPK downstream targets are modified at this dose, showing a discrepancy between hypertrophy prevention and known AMPK target regulation. The same discrepancy was observed in ARVM at low dose of A-769662.
Conclusion:
Collectively, our results using low dose of A-769662 suggest a yet to be identified mechanism by which AMPK can regulate cardiac hypertrophy. AMPK is activated during platelet aggregation and controls the phosphorylation state of key cytoskeletal targets. CaMKKβ is responsible for thrombin-induced AMPK activation. Substantial differences have been observed between human and murine platelets. This study aims to bring out the differences in AMPK signalling pathway between human and murine platelets. Only α1 catalytic subunit of AMPK is present in human platelets. Thrombin induces a dramatic AMPKα1 activation and subsequent acetyl-CoA carboxylase (ACC) phosphorylation, while thromboxane A2 (U46619) and collagen exert a marginal effect on both enzymes. ADP has no effect at all. These differences cannot be entirely related to a lower calcium production in response to U46619, collagen and ADP. Indeed, U46619 increases calcium with a similar extent than thrombin while it does not modify ACC phosphorylation. PAR1 but not PAR4-activating peptide reproduces the effect of thrombin on ACC. In addition, inhibition of CaMKKβ/AMPKα1 activation blunts platelet aggregation in response to thrombin and does not affect the response upon stimulation by the other agonists.
Murine platelets express AMPKα1 and AMPKα2. AMPK can be activated either by thrombin or U46619 or collagen but not by ADP. The absence of AMPKα1 blocks ACC phosphorylation induced by the three agonists. It mainly inhibits the thrombin-induced platelet aggregation but also significantly reduces aggregation in response to U46619 and collagen. The absence of AMPKα2 does not affect the increase in ACC phosphorylation, whatever the agonist used.
Conclusions:
AMPKα1 is the sole catalytic subunit of AMPK expressed in human platelets and is activated by thrombin through PAR1. Murine platelets contain both catalytic subunits although α1 plays a predominant role. In mice, thrombin is not the predominant AMPK activator probably because of the difference in the type of PAR expression. Signalling events of mouse platelets can diverge from those of human platelets. 
